Reduced Intensity Allogeneic Transplantation Provides High Event-Free And Overall Survival In Patients With Advanced Indolent B Cell Malignancies: CALGB 109901.

February 16, 2011

BlankReduced Intensity Allogeneic Transplantation Provides High Event-Free And

Overall Survival In Patients With Advanced Indolent B Cell Malignancies: CALGB

109901.

T Shea, J , P Westervelt, S Farag, J McCarty, A Bashey, L Isola, LA

Baxter-Lowe, M , K Owzar, C Linker, and for the Cancer and Leukemia Group

B, Chicago, IL.

Biol Blood Marrow Transplant, February 2, 2011; .

University of North Carolina School of Medicine, Chapel Hill, NC; supported by

CA47559.

CALGB conducted a Phase II study to evaluate the safety and efficacy of a

reduced-intensity conditioning regimen with allogeneic transplantation to treat

patients with recurrent low grade B cell malignancies. Patients over age 18 with

a diagnosis of relapsed, chemotherapy-sensitive disease underwent

transplantation with a matched sibling donor and conditioning with

cyclophosphamide (1 g/m(2)/d x 3) and fludarabine phosphate (25 mg/m(2)/d x 5).

GVH prophylaxis included cyclosporine or tacrolimus plus low-dose methotrexate.

Forty-four evaluable patients with a median age of 53 and median of two prior

regimens were accrued. Sixteen patients had follicular NHL and 28 had

histologies including 7 indolent B cell lymphomas, 4 mantle cell, 15 chronic

lymphocytic leukemia, and 2 prolymphocytic leukemia pts. The six-month

treatment-related mortality (TRM) was 2.4% and three-year TRM was 9%. Three-year

event-free and overall survival were.75 and.81 for the follicular patients,.59

and.71 for the CLL/PLL patients, and.55 and.64 for the other histologies. The

incidence of grade 2-4 acute graft vs host disease (GVHD) was 29% and extensive

chronic GVHD was 18%. This report demonstrates that allogeneic sibling

transplantation with a reduced intensity conditioning regimen is safe and

efficacious for patients with advanced indolent B cell malignancies enrolled on

a ative Group study.

PMID: 21296675

Recommended Posts